Metagenomi TherapeuticsMGX
13F holders, Q2 2026 (June 30)At the end of Q2 2026, 43 institutions reported holding Metagenomi Therapeutics Inc. (MGX) in their 13F filings, down 5 from Q1 2026. 4 opened new positions and 8 sold out. The largest holders were Vanguard Capital Management LLC ($1.3M), Renaissance Technologies ($883K) and Catalio Capital Management, LP ($630K). 3 famous investors held it, including Jim Simons / Peter Brown (0.0% of Renaissance Technologies's portfolio), Israel Englander (0.0% of Millennium Management's portfolio) and Ken Griffin (0.0% of Citadel Advisors's portfolio).
- Company
- Metagenomi Therapeutics Inc.
- CUSIP
- 59102M104
- Latest filing quarter
- Q2 2026
History
Number of 13F holders
Total Exit/New Position Q1 2026 → Q2 2026
| Institutions | Total Value | |
|---|---|---|
| New Positions | 4 | $124K |
| Exits | 8 | $96K |
All 13F filers, Q1 2026 → Q2 2026: 411,447 shares bought and 612,746 shares sold, net −201,299 shares. Counts holders who added, trimmed, opened or closed a position; split-adjusted.
Ownership 43 holders
| Vanguard Capital Management LLC | 0.00% | Add +1.9% | 1,077,700 | $1.3M |
| Renaissance Technologies | 0.00% | Reduce -5.8% | 742,400 | $883K |
| Catalio Capital Management, LP | 0.12% | No change | 528,993 | $630K |
| Peapod Lane Capital LLC | 0.42% | Add +1.6% | 525,024 | $625K |
| Two Sigma Investments, LP | 0.00% | Add +3.4% | 513,701 | $611K |
| Bridgeway Capital Management, LLC | 0.01% | Add +1.1% | 400,300 | $476K |
| Wells Fargo & Company | 0.00% | Add +87.8% | 379,508 | $452K |
| Geode Capital Management, LLC | 0.00% | Reduce -19.4% | 288,665 | $344K |
| Pura Vida Investments, LLC | 0.85% | No change | 264,391 | $315K |
| BlackRock, Inc. | 0.00% | Add +11.9% | 257,631 | $307K |
| Vanguard Fiduciary Trust Co. | 0.00% | Add +0.6% | 171,251 | $204K |
| Jacobs Levy Equity Management, Inc. | 0.00% | Reduce -58.1% | 160,000 | $190K |
| State Street Corp. | 0.00% | Reduce -0.5% | 119,850 | $143K |
| Millennium Management | 0.00% | Reduce -33.0% | 114,025 | $136K |
| Man Group plc | 0.00% | Add +38.8% | 109,130 | $130K |
| Resolute Advisors LLC | 0.03% | No change | 89,944 | $107K |
| Marquette Asset Management, LLC | 0.01% | New | 72,121 | $86K |
| Northern Trust Corp. | 0.00% | Reduce -8.3% | 68,938 | $82K |
| RBF Capital, LLC | 0.00% | No change | 64,021 | $76K |
| XTX Topco Ltd | 0.00% | Add +37.3% | 55,707 | $66K |
| BBR Partners, LLC | 0.00% | No change | 53,403 | $64K |
| Jane Street Group, LLC | 0.00% | Reduce -74.7% | 38,396 | $46K |
| Fortitude Advisory Group L.L.C. | 0.02% | No change | 37,190 | $44K |
| Citadel Advisors | 0.00% | Add +5.0% | 17,851 | $21K |
| Qube Research & Technologies Ltd | 0.00% | New | 16,850 | $20K |
| UBS Group AG | 0.00% | Reduce -1.9% | 15,793 | $19K |
| Two Sigma Securities, LLC | 0.00% | New | 15,173 | $18K |
| Vanguard Global Advisers, LLC | 0.00% | No change | 13,392 | $16K |
| Dimensional Fund Advisors LP | 0.00% | No change | 12,797 | $15K |
| Peak Planning Group, LLC | 0.00% | No change | 12,500 | $15K |
| Meeder Asset Management Inc. | 0.00% | No change | 5,496 | $7K |
| Morgan Stanley | 0.00% | Reduce -80.8% | 5,302 | $6K |
| Tower Research Capital LLC (TRC) | 0.00% | Add +12519.0% | 5,300 | $6K |
| US Bancorp \de | 0.00% | No change | 4,500 | $5K |
| Osaic Holdings, Inc. | 0.00% | Reduce -34.6% | 1,891 | $2K |
| JPMorgan Chase & Co. | 0.00% | No change | 1,596 | $2K |
| FMR LLC | 0.00% | Reduce -87.5% | 588 | $700 |
| Jones Financial Companies LLLP | 0.00% | No change | 500 | $625 |
| Allworth Financial LP | 0.00% | No change | 500 | $595 |
| BNP Paribas Financial Markets | 0.00% | Reduce -32.6% | 207 | $246 |
| Barclays PLC | 0.00% | New | 167 | $199 |
| Caitong International Asset Management Co., Ltd | 0.00% | Add +100.0% | 8 | $10 |
| Optiver Holding B.V. | 0.00% | Reduce -88.9% | 2 | $2 |
"% of holder's portfolio" is MGX's weight in each manager's 13F, not the share of Metagenomi Therapeutics Inc. the manager owns.